TITLE

Delivering tamoxifen within solid lipid nanoparticles

AUTHOR(S)
Abbasalipourkabir, Roghayeh; Salehzadeh, Aref; Abdullah, Rasedee
PUB. DATE
April 2011
SOURCE
Pharmaceutical Technology Europe;Apr2011, Vol. 23 Issue 4, p22
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Solid lipid nanoparticles (SLNs) have been proposed as an alternative colloidal drug-delivery system for water-soluble drugs. The aim of this study was to prepare and characterise physiochemically and biologically tamoxifen-loaded SLNs to evaluate their effectiveness as a drug-delivery system to treat breast cancers.
ACCESSION #
59964373

 

Related Articles

  • Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain Cancer Free, Study Shows; Results From Pfizer-Sponsored Study Challenge Standard Tamoxifen Therapy.  // Ascribe Newswire: Medicine;3/22/2004, p22 

    Post-menopausal breast cancer patients who switched from tamoxifen to Aromasin had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen, according to new data published in the March 22, 2004 issue of the "New England...

  • Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score. Barginear, M. F.; Jaremko, M.; Peter, I.; Yu, C.; Kasai, Y.; Kemeny, M.; Raptis, G.; Desnick, R. J. // Clinical Pharmacology & Therapeutics;Oct2011, Vol. 90 Issue 4, p605 

    Tamoxifen (Tam), the major drug for estrogen receptor (ER)-positive breast cancer, is converted to its active metabolites, Z- and Z′-endoxifen and 4-OH-Tam isomers, primarily by cytochrome P450 CYP2D6. In 117 patients taking 20 mg/day of Tam, we determined CYP2D6 genotypes and measured the...

  • Fulvestrant: A Viewpoint by Roger W. Blamey. Blamey, R.W. // Drugs;Apr2001, Vol. 61 Issue 6, p814 

    Presents information on fulvestrant, an anti-estrogen antagonist, indicated for treating breast cancer. Comparison between fulvestrant and tamoxifen as estrogen receptors; Limitations of the effect of the fulvestrant.

  • POEM. Coombes, R.C.; Hall, E.; Gibson, L.J. // BMJ: British Medical Journal (International Edition);7/10/2004, Vol. 329 Issue 7457, p0 

    Presents a summary of a study on the use of exemestane in the years 2-5 after breast cancer. Question; Synopsis; Bottom line that exemestane does improve outcomes for postmenopausal women with oestrogen receptor positive breast cancer after 2-3 years of treatment with tamoxifen; Level of evidence.

  • Tamoxifen Resistance in Breast Cancer: Elucidating Mechanisms. Dorssers, L.C.J.; van der Flier, S.; Brinkman, A.; van Agthoven, T.; Veldscholte, J.; Berns, E.M.J.J.; Klijn, J.G.M.; Beex, L.V.A.M.; Foekens, J.A. // Drugs;Sep2001, Vol. 61 Issue 12, p1721 

    Tamoxifen has been used for the systemic treatment of patients with breast cancer for nearly three decades. Treatment success is primarily dependent on the presence of the estrogen receptor (ER) in the breast carcinoma. While about half of patients with advanced ER-positive disease immediately...

  • Tamoxifen Update. Sugerman, Deborah Tolmach // JAMA: Journal of the American Medical Association;8/28/2013, Vol. 310 Issue 8, p866 

    The article provides information on the drug Tamoxifen. Tamoxifen is a drug that blocks the effects of the hormone estrogen. It is used as a treatment for breast cancer patients whose tumors have estrogen receptors, called ER positive. It is often used after surgery or radiation therapy and also...

  • Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Mojarrad, Majid; Momeny, Majid; Mansuri, Fatemeh; Abdolazimi, Yassan; Tabrizi, Mina Hajifaraj; Ghaffari, Seyed Hamidollah; Tavangar, Seyed Mohammad; Modarressi, Mohammad Hussein // Medical Oncology;Jun2010, Vol. 27 Issue 2, p474 

    Tamoxifen is the most common antiestrogen used in the treatment of estrogen-positive breast cancer but its adverse effects and also resistance to this drug are serious challenges in the treatment of breast cancer. Characterization of mechanisms responsible for these adverse effects can lead to...

  • anti-oestrogen drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p58 

    An encyclopedia entry for an "anti-oestrogen drugs" is presented. They refer to a group of drugs that contrast the action of the hormone oestrogen. Tamoxifen, which is used in the treatment of certain breast cancers, is said to be the most important of these drugs.

  • Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen. J Weaver; J M McHugo; T J Clark // British Journal of Radiology;May2005, Vol. 78 Issue 929, p394 

    The incidence of endometrial pathology is increased in women with tamoxifen-induced post-menopausal bleeding (PMB). The aim of this study was to determine the accuracy of transvaginal ultrasound (TVS) in diagnosing endometrial pathology in symptomatic women taking tamoxifen, using endometrial...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics